Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AstraZeneca Announces Partnership with Singapore Institutions to Develop Anti-Cancer Compounds

Published: Tuesday, August 19, 2008
Last Updated: Tuesday, August 19, 2008
Bookmark and Share
The collaboration aims to further build AstraZeneca's drug development capabilities in Asia and speed up access to new medicines of potential benefit to patients.

AstraZeneca has announced a new partnership with the National Cancer Centre Singapore (NCCS) and the National University Hospital (NUH) to develop anti-cancer compounds.

The collaboration, which is spelt out in a Memorandum of Understanding (MOU), aims to further build AstraZeneca's drug development capabilities in Asia and ultimately speed up access to new medicines of potential benefit to patients with inoperable Hepatocellular Carcinoma (HCC).

HCC is a cancer that is particularly prevalent in Asia and accounts for approximately one million deaths annually worldwide. Studies have also shown that more than 90 per cent of those afflicted with the cancer die within five years due to its inoperability.

Under the MOU, AstraZeneca and the Singapore institutions will be entering into a collaborative agreement that spans both clinical and pre-clinical development activities.

The partnership also includes a Training Programme placement with the Manchester Cancer Research Centre, with whom AstraZeneca has a formal research alliance. Supported in part by the Singapore Economic Development Board, the training programme seeks to train a pool of clinical research professionals for both private-sector and public-sector research labs.

"Singapore is one of Asia's fastest growing bio-clusters and offers excellent IP protection, a population base representative of Asia, world-class scientific and clinical infrastructure as well as access to global talent," said Mr. Yeoh Keat Chuan, Executive Director, Biomedical Sciences, Singapore Economic Development Board.

"AstraZeneca joins an expanding base of leading pharmaceutical and biotechnology companies that have chosen to develop new drugs and therapies in Singapore. It is a strong testament of Singapore's capabilities in translational and clinical research, particularly in applications for diseases prevalent in Asia."

Under the terms of the clinical development collaboration, two of Singapore's leading research institutions - the NCCS and NUH - will be given access to AstraZeneca compounds which have already undergone initial clinical testing in the West.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AstraZeneca Buys Rights to Almirall Respiratory Franchise
AstraZeneca agrees an initial consideration of $875 million on completion, which may rise to $1.22 billion in development, launch, and sales-related milestones.
Monday, August 04, 2014
AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance Assets
Global agreement strengthens AstraZeneca’s commitment to diabetes.
Monday, December 23, 2013
AstraZeneca Announces Changes to Senior Executive Team
Company’s President and Executive Vice President will leave the company at the end of January.
Monday, January 28, 2013
AstraZeneca Appoints Pascal Soriot CEO
Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
Tuesday, August 28, 2012
AstraZeneca to Provide UK Academics with Access to Compound Library
Their groundbreaking new collaboration with the Medical Research Council (MRC) will see the company providing the UK academic sector with access to 22 drugs.
Friday, December 09, 2011
Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Late Stage Next Generation Anti-Infective
The definitive collaboration agreement will co-develop and commercialize ceftaroline in all markets outside the U.S., Canada and Japan.
Thursday, August 13, 2009
IRESSA Receives Marketing Authorization for the Treatment of Non-Small Cell Lung Cancer in Europe
European Commission grants marketing authorization for the oral anti-cancer drug.
Tuesday, July 07, 2009
BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
BioDuro and AstraZeneca announced that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications.
Friday, March 27, 2009
AstraZeneca Licenses Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights.
Tuesday, February 10, 2009
AstraZeneca and MAP Collaborate for Development and Commercialization of Unit Dose Budesonide
Unit Dose Budesonide is being developed as a potential treatment for pediatric asthma and is currently in Phase III clinical development.
Monday, December 22, 2008
Palatin Technologies Announces Amendment Expanding AstraZeneca Obesity Collaboration
AstraZeneca and Palatin amend their collaboration agreement to discover, develop and commercialize compounds that target melanocortin receptors.
Wednesday, July 02, 2008
AstraZeneca Submits sNDAs for Seroquel XR™ for the Treatment of Bipolar Mania and Bipolar Depression
AstraZeneca has submitted two separate supplemental New Drug Applications to the US FDA for once-daily Seroquel XR™ Extended-Release Tablets.
Thursday, January 03, 2008
AstraZeneca and Palatin Announce Collaboration to Discover, Develop and Commercialise Obesity Compounds
The collaboration is based on Palatin's melanocortin receptor Obesity programme and includes access to compound libraries, core technologies and expertise.
Tuesday, February 06, 2007
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!